Perinatal toxicity of ethylene glycol dimethyl ether in the rat

Glymes as Versatile Solvents for Chemical Reactions and Processes: from the Laboratory to Industry

Glymes, also known as glycol diethers, are saturated non-cyclic polyethers containing no other functional groups. Most glymes are usually less volatile and less toxic than common laboratory organic solvents; in this context, they are more environmentally benign solvents. However, it is also important to point out that some glymes could cause long-term reproductive and developmental damages despite their low acute toxicities. Glymes have both hydrophilic and hydrophobic characters that common organic solvents are lack of. In addition, they are usually thermally and chemically stable, and can even form complexes with ions. Therefore, glymes are found in a broad range of laboratory applications including organic synthesis, electrochemistry, biocatalysis, materials, and Chemical Vapor Deposition (CVD), etc. In addition, glyme are used in numerous industrial applications, such as cleaning products, inks, adhesives and coatings, batteries and electronics, absorption refrigeration and heat pumps, as well as pharmaceutical formulations, etc. However, there is a lack of comprehensive and critical review on this attractive subject. This review aims to accomplish this task by providing an in-depth understanding of glymes' physicochemical properties, toxicity and major applications.

Glymes as benign co-solvents for CaO-catalyzed transesterification of soybean oil to biodiesel

The base (such as CaO)-catalyzed heterogeneous preparation of biodiesel encounters a number of obstacles including the need for CaO pretreatment and the reactions being incomplete (typically 90-95% yields). In this study, a number of glymes were investigated as benign solvents for the CaO-catalyzed transesterification of soybean oil into biodiesel with a high substrate loading (typically soybean oil >50% v/v). The triglyceride-dissolving capability of glymes led to a much faster reaction rate (>98% conversions in 4h) than in methanol alone (typically 24h) and minimized the saponification reaction when catalyzed by anhydrous CaO or commercial lime without pre-activation. The use of glyme (e.g. P2) as co-solvent also activates commercial lime to become an effective catalyst without calcination pretreatment. The SEM images suggest a dissolution-agglomeration process of CaO surface in the presence of P2, which could remove the CaCO3 and Ca(OH)2 layer coated on the surface of lime.

Correlation between urinary methoxyacetic acid and exposure of ethylene glycol dimethyl ether in a lithium battery plant

OBJECTIVE

To examine the correlation between airborne ethylene glycol dimethyl ether (EGdiME) exposures and the urinary methoxyacetic acid (MAA) and to approach the issue of a permissible exposure limit for EGdiME.

METHODS

The survey was conducted on Thursday. Workers occupationally exposed to EGdiME, as well as nonexposed controls, were studied in combination with one of the authors, who was coincidentally exposed to EGdiME while carrying out the study. Air levels of EGdiME were determined by personal sampling on passive gas tubes. Urine was collected from nine control subjects and ten workers immediately before and after the shift, and from one of the authors at intervals during 12 h. The analyses of EGdiME in air and MAA in urine were performed by gas chromatography with flame ionization detection.

RESULTS

The time-weighted average (TWA) air levels of EGdiME ranged from 0.7 to 10.5 ppm during 8 h work shifts. The urinary levels of MAA in one of the authors increased continuously during exposure and after the end of exposure. The levels of urinary MAA in the exposed workers were significantly higher than those in the control subjects. On the other hand, the postshift values were higher than the preshift values in the exposed workers, but the difference was not significant. A linear correlation was found between the TWA air levels of EGdiME and creatinine-adjusted MAA levels in urine collected at the end of the shift (r = 0.933; P < 0.0001). According to our equation, a linear extrapolation to the biological limit value recommended by Shih et al. (1999) of 40 mg MAA/g crea indicated an average inhalation exposure to EGdiME over the workweek of 12 ppm.

CONCLUSIONS

These results indicate that the determination of MAA in urine is suitable for use in the biological monitoring of EGdiME exposure.

Urinary methoxyacetic acid as an indicator of occupational exposure to ethylene glycol dimethyl ether

OBJECTIVE

To investigate whether methoxyacetic acid (MAA) is the metabolite of ethylene glycol dimethyl ether (EGdiME) in humans and whether its metabolite in urine can be used as a biomarker for exposure to EGdiME.

METHODS

Workers occupationally exposed to EGdiME, as well as nonexposed controls, were studied. Urine samples were collected from 20 control subjects and, on Friday postshift, from 14 workers. The identification and quantification of the metabolite were performed by gas chromatography/mass spectrometry (GC/MS) and GC/FID, respectively. Air samples were collected on activated charcoal tubes by area sampling with battery-operated pumps. The glycol ether was analyzed by GC/FID.

RESULTS

GC/MS clearly showed the metabolite of EGdiME to be MAA. Urinary MAA levels in the control subjects (background levels) were 0.0-0.3 mg/g crea. The levels of urinary MAA in the solvent-exposed workers were significantly (P<0.0001) higher than those in the control subjects. In the eight workers exposed to an average of 0.3 ppm of EGdiME and the six workers exposed to an average of 2.9 ppm, the mean urinary MAA level was 1.08 (range 0.6-1.5) mg/g crea and 9.33 (range 5.7-18.1) mg/g crea, respectively. These results can be explained by differences in the exposure intensity.

CONCLUSIONS

Our results suggest that MAA is the metabolite of EGdiME, and that MAA in urine may be used for biological monitoring of EGdiME exposures.

Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats

BACKGROUND

Lasofoxifene is a nonsteroidal selective estrogen receptor modulator (SERM). With high affinity to the alpha and beta human estrogen receptors and greater potency than other SERMs, lasofoxifene is potentially a superior treatment for postmenopausal osteoporosis. In light of the known effects of estrogen-modulating compounds on female reproductive indices, two studies were conducted to evaluate the effects of lasofoxifene on female rat cyclicity, reproduction, and parturition.

METHODS

One study evaluated effects of lasofoxifene on estrous cyclicity, and the second study assessed effects on implantation and parturition. In the cyclicity study, lasofoxifene was administered to female rats at doses of 0.1, 0.3, and 1.0 mg/kg/day for 14 consecutive days. After treatment, there was a 3-week reversibility phase followed by a mating phase. In the implantation study, lasofoxifene was administered to pregnant female rats at doses of 0.01, 0.03, and 0.1 mg/kg/day for 7 consecutive days (gestation day [GD] 0-6). Some animals were euthanized on GD 21, and the remainder of the group was allowed to deliver the F1 generation. Several developmental indices were evaluated in the F1 pups through post-natal day (PND) 21.

RESULTS

In the cyclicity study, all lasofoxifene-treated females were anestrous by Study Day 7 (1.0 mg/kg) or 9 (0.3 and 0.1 mg/kg). The reversibility phase resulted in restoration of normal estrous cycles by the end of 1 (0.1 mg/kg) or 2 weeks (0.3 and 1.0 mg/kg). During the mating phase, no adverse effects occurred in pregnancy success or reproductive parameters. In the implantation study, all doses of lasofoxifene increased pre- and post-implantation losses, increased gestation length, and reduced litter size. None of the developmental parameters measured on the F1 generation was adversely affected.

CONCLUSION

Lasofoxifene reversibly altered the estrous cycle and inhibited implantation, consistent with what would be expected from a member of the SERM class.

Species and strain comparisons of immunosuppression by 2-methoxyethanol and 2-methoxyacetic acid

2-Methoxyethanol (ME) and its principal metabolite 2-methoxyacetic acid (MAA) have been shown in our laboratory to be immunosuppressive in male Fischer 344 rats. In this study several strains of 12-week-old female rats and mice were used to compare the immunosuppressive activity of equimolar concentrations of ME and MAA on the trinitrophenyl-lipopolysaccharide (TNP-LPS) antibody plaque-forming cell (PFC) response, which we previously demonstrated to be a sensitive end point. Female inbred Lewis, Fischer 344 and Wistar/Furth, and outbred Sprague-Dawley rats were dosed by gavage with either ME or MAA at dosages of 0.33 to 2.64 mmol/kg/day for 10 consecutive days. Female inbred C3H and C57BL/6J, hybrid B6C3F1, and outbred CD-1 mice were similarly dosed with equimolar dosages of 0.66 to 5.28 mmol/kg/day ME or MAA. All animals were immunized on day 9 of dosing and PFC responses evaluated 3 days later. Suppression of the PFC response was observed in all strains of rats at 2.64 mmol/kg/day ME or MAA. Lewis and Wistar/Furth rats were found to be the most sensitive strains with suppression at levels as low as 0.66 mmol/kg/day ME or MAA. While ME and MAA dosing resulted in suppression of the TNP PFC response in all the rat strains tested, such treatment did not suppress this PFC response in any of the mouse strains examined. These results indicate that under the conditions of this study rats, but not mice, are immunosuppressed by ME and MAA exposure, and that the susceptibility to immunosuppression differs among rat strains.